Latest Interferon beta-1a Stories
Biogen Idec (NASDAQ: BIIB) today announced that data was presented from the ASSURANCE (ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs) study, showing the long-term benefits of AVONEX(R) (interferon beta-1a IM) therapy in patients with relapsing multiple sclerosis (MS) for up to 15 years.
Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada.
Merck KGaA has announced that its Merck Serono division has completed patient enrollment in the Reflex trial of Rebif in patients at risk of developing multiple sclerosis.
Bayer HealthCare Pharmaceuticals Inc.
Biogen Idec has completed enrollment in the Assurance trial, a long-term follow-up study which will assess up to 15 years of Avonex treatment in an effort to provide detailed data on the long-term efficacy of the drug.
Biogen Idec today announced that enrollment is complete in the ASSURANCE trial, a long-term follow-up study which will assess up to 15 years of AVONEX(R) (interferon beta-1a) treatment in an effort to provide detailed data on the long term efficacy of the drug.
By Blasier, Mary Gail Key Words: Multiple sclerosis, central nervous system, disease modifying therapies, quality of life. Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), which is composed of the brain, optic nerves, and spinal cord (Graham, 2009).
Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial.
U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease.
LOS ANGELES (Reuters) - Teva Pharmaceutical Industries Ltd. said on Wednesday that its multiple sclerosis drug Copaxone was shown in a clinical trial to be effective in patients who had stopped responding to Avonex, a competing drug made by Biogen Idec.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).